Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395859 | 0.83 | FLT3 (0.71) | FLT3PDGFRBPDGFRA | |
| SCHEMBL6400999 | 0.81 | FLT3 (0.59) | FLT3HRH4 | |
| SCHEMBL1144995 | 0.81 | HPGD (0.62) | FLT3HRH4 | |
| SCHEMBL17324813 | 0.81 | FLT3 (0.61) | FLT3HRH4 | |
| SCHEMBL31060426 | 0.80 | FLT3 (1.00) | FLT3PDGFRBPDGFRAFGFR1 | |
| SCHEMBL370573 | 0.80 | FLT3 (1.00) | FLT3PDGFRBPDGFRAFGFR1 | |
| SCHEMBL5355599 | 0.80 | GLA (0.68) | FLT3HRH4 | |
| Methane SCHEMBL22343918 | 0.78 | FLT3 (0.96) | FLT3PDGFRBPDGFRAFGFR1 | |
| SCHEMBL6865499 | 0.78 | PDGFRB (0.63) | FLT3PDGFRBPDGFRAHRH4 | |
| SCHEMBL426783 | 0.78 | PDGFRB (0.74) | FLT3PDGFRBPDGFRAFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812243-B2 | AS TYROSINE KINASE INHIBITORS; FOR THERARPY OF TUMORS, ARTERIOSCLEROSIS, RESTENOSIS AFTER BALLOON ANGIOPLASTY, ARTHRITIS AND FIBROTIC DISEASES | ZENTARIS AG (DE) | 2004-11-02 | — | — | US | disclosed |
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | ZENTARIS AG (DE) | 2003-01-09 | — | — | US | disclosed |
| EP-1109785-B1 | INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MALIGNANT AND OTHER DISEASES CAUSED BY PATHOLOGICAL CELL PROLIFERATION | ZENTARIS AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6407102-B1 | TYROSINE KINASE AND PLATELET-DERIVED GROWTH FACTOR INHIBITORS; ANTICARCINOGENIC, ANTITUMOR, ANTIARTHRITIC AND ANTIPROLIFERATIVE AGENTS; RESTENOSIS, ARTERIOSCLEROSIS | ZENTARIS AG (DE) | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008898-A1 | Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation | MKI67, IDO1, CCNI | FLT3 230/4885PDGFRB 474/4885PDGFRA 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.